Abstract
Major depressive disorder (MDD) is a prevalent mood disorder that is associated with differential prefrontal brain expression patterns1. Treatment of MDD includes a variety of biopsychosocial approaches. In medical practice, antidepressant drugs are the most common treatment for depressive episodes, and they are among the most prescribed medications in North America2,3. Although antidepressants are clearly effective, particularly for moderate to severe depressive episodes, there is variability in how individuals respond to antidepressant treatment. Failure to respond has individual, economic and social consequences for patients and their families4. Several lines of evidence demonstrate that genes are regulated through the activity of microRNAs (miRNAs), which act as fine-tuners and on-off switches of gene expression5,6,7. Here we report on complementary studies using postmortem human brain samples, cellular assays and samples from clinical trials of patients with depression and show that miR-1202, a miRNA specific to primates and enriched in the human brain, is differentially expressed in individuals with depression. Additionally, miR-1202 regulates expression of the gene encoding metabotropic glutamate receptor-4 (GRM4) and predicts antidepressant response at baseline. These results suggest that miR-1202 is associated with the pathophysiology of depression and is a potential target for new antidepressant treatments.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Schmidt, H.D., Shelton, R.C. & Duman, R.S. Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 36, 2375–2394 (2011).
Pincus, H.A. et al. Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. J. Am. Med. Assoc. 279, 526–531 (1998).
Banthin, J.S. & Miller, G.E. Trends in prescription drug expenditures by Medicaid enrollees. Med. Care 44, I27–I35 (2006).
Chen, Y. et al. Utilization, price, and spending trends for antidepressants in the US Medicaid Program. Res. Social Adm. Pharm. 4, 244–257 (2008).
Qureshi, I.A. & Mehler, M.F. Emerging roles of non-coding RNAs in brain evolution, development, plasticity and disease. Nat. Rev. Neurosci. 13, 528–541 (2012).
Esteller, M. Non-coding RNAs in human disease. Nat. Rev. Genet. 12, 861–874 (2011).
He, L. & Hannon, G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 5, 522–531 (2004).
Kozomara, A. & Griffiths-Jones, S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 39, D152–D157 (2011).
Kent, W.J. et al. The human genome browser at UCSC. Genome Res. 12, 996–1006 (2002).
Meyer, L.R. et al. The UCSC Genome Browser database: extensions and updates 2013. Nucleic Acids Res. 41, D64–D69 (2013).
Pasquinelli, A.E. et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 408, 86–89 (2000).
Dweep, H., Sticht, C., Pandey, P. & Gretz, N. miRWalk–database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J. Biomed. Inform. 44, 839–847 (2011).
Betel, D., Wilson, M., Gabow, A., Marks, D.S. & Sander, C. The microRNA.org resource: targets and expression. Nucleic Acids Res. 36, D149–D153 (2008).
Miranda, K.C. et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 126, 1203–1217 (2006).
Krüger, J. & Rehmsmeier, M. RNAhybrid: microRNA target prediction easy, fast and flexible. Nucleic Acids Res. 34, W451–W454 (2006).
Lewis, B.P., Burge, C.B. & Bartel, D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15–20 (2005).
Ernst, C. et al. Confirmation of region-specific patterns of gene expression in the human brain. Neurogenetics 8, 219–224 (2007).
Ernst, C. et al. Alternative splicing, methylation state, and expression profile of tropomyosin-related kinase B in the frontal cortex of suicide completers. Arch. Gen. Psychiatry 66, 22–32 (2009).
Sequeira, A. et al. Patterns of gene expression in the limbic system of suicides with and without major depression. Mol. Psychiatry 12, 640–655 (2007).
Sequeira, A. et al. Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS ONE 4, e6585 (2009).
Pilc, A., Chaki, S., Nowak, G. & Witkin, J.M. Mood disorders: regulation by metabotropic glutamate receptors. Biochem. Pharmacol. 75, 997–1006 (2008).
Davis, M.J., Haley, T., Duvoisin, R.M. & Raber, J. Measures of anxiety, sensorimotor function, and memory in male and female mGluR4−/− mice. Behav. Brain Res. 229, 21–28 (2012).
Davis, M.J. et al. Role of mGluR4 in acquisition of fear learning and memory. Neuropharmacology 66, 365–372 (2013).
Célanire, S. & Campo, B. Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders. Expert Opin. Drug Discov. 7, 261–280 (2012).
Lopez, J.P. et al. Epigenetic regulation of BDNF expression according to antidepressant response. Mol. Psychiatry 18, 398–399 (2013).
Bocchio-Chiavetto, L. et al. Blood microRNA changes in depressed patients during antidepressant treatment. Eur. Neuropsychopharmacol. 23, 602–611 (2013).
Soreq, H. & Wolf, Y. NeurimmiRs: microRNAs in the neuroimmune interface. Trends Mol. Med. 17, 548–555 (2011).
Labuda, M. et al. Linkage disequilibrium analysis in young populations: pseudo-vitamin D-deficiency rickets and the founder effect in French Canadians. Am. J. Hum. Genet. 59, 633–643 (1996).
López-Romero, P. Pre-processing and differential expression analysis of Agilent microRNA arrays using the AgiMicroRna Bioconductor library. BMC Genomics 12, 64 (2011).
Leek, J.T. & Storey, J.D. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet. 3, 1724–1735 (2007).
Smyth, G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, Article3 (2004).
Bozdogan, H. Model Selection and akaike's information criterion (AIC): the general theory and its analytical extensions. Psychometrika 52, 345–370 (1987).
Chen, C. et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33, e179 (2005).
Acknowledgements
We are grateful for the contributions made by the families consenting to donate brain tissue to the Douglas-Bell Canada Brain Bank. We thank A. Ryan and C. Ernst at McGill University for their contributions of chick brain tissue and human NPCs, respectively. This work was supported by operating grants from the Canadian Institutes of Health Research (CIHR) (2008#190734 and 2013#311113), as well as support from the Fonds de recherche du Québec Santé (FRQS) through its network program, Quebec Network on Suicide, Mood Disorders and Related Disorders (RQSHA). J.P.L. received doctoral funding awards from FRQS and CIHR. G.T. is an FRQS chercheur national.
Author information
Authors and Affiliations
Contributions
J.P.L. was involved in conducting and coordinating all aspects of the research, including testing feasibility and planning the experiments, processing human and animal tissues, validating results, executing most molecular and cellular experiments, analyzing data, and interpreting and preparing the manuscript. R.L. and P.P. were responsible for bioinformatics and statistical analysis of the miRNA microarray data. C.C. planned and carried out antidepressant treatment of human NPCs and screening for cytotoxic effects. L.C. performed the agonist and antagonist treatment of human NPCs. C.C., L.C. and G.M. were responsible for the maintenance of human NPCs and knockdown cell lines. C.F., E.V. and S.E.M. were responsible for immunocytochemistry, western blotting and imaging analysis. J.P.Y. and V.Y. conducted the experiments involving overexpression and neutralization of miR-1202 effects on HEK 293 cells. B.L. and N.M. participated in the design of the study and interpretation of the data. G.T. conceived, supported and designed this study and was responsible for overseeing the experiments, including all aspects of design, interpretation of data, and preparation of the manuscript and figures. All authors discussed the results presented in the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Tables 1–6 and Supplementary Figures 1–12. (PDF 1433 kb)
Rights and permissions
About this article
Cite this article
Lopez, J., Lim, R., Cruceanu, C. et al. miR-1202 is a primate-specific and brain-enriched microRNA involved in major depression and antidepressant treatment. Nat Med 20, 764–768 (2014). https://doi.org/10.1038/nm.3582
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3582
This article is cited by
-
SNORA69 is up-regulated in the lateral habenula of individuals with major depressive disorder
Scientific Reports (2024)
-
miR-483-5p offsets functional and behavioural effects of stress in male mice through synapse-targeted repression of Pgap2 in the basolateral amygdala
Nature Communications (2023)
-
Stress, microRNAs, and stress-related psychiatric disorders: an overview
Molecular Psychiatry (2023)
-
Electroconvulsive Stimulation in Rats Induces Alterations in the Hippocampal miRNome: Translational Implications for Depression
Molecular Neurobiology (2023)
-
miR-323a regulates ERBB4 and is involved in depression
Molecular Psychiatry (2021)